MARKET

ALEC

ALEC

Alector
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.75
+0.19
+1.64%
Opening 13:13 07/07 EDT
OPEN
11.93
PREV CLOSE
11.56
HIGH
12.04
LOW
11.69
VOLUME
118.94K
TURNOVER
893.64K
52 WEEK HIGH
39.74
52 WEEK LOW
7.50
MARKET CAP
967.34M
P/E (TTM)
-34.1669
1D
5D
1M
3M
1Y
5Y
Expert Ratings for Alector
Within the last quarter, Alector (NASDAQ:ALEC) has observed the following analyst ratings:
Benzinga · 9m ago
--Mizuho Securities Initiates Alector at Buy with $15 Price Target
MT Newswires · 6h ago
Alzheimer’s drug developers are on decline after Roche setback
A group of low cap biotechs are leading a selloff among Alzheimer’s drug developers after Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced on Thursday that their experimental drug for the memory robbing disease
Seekingalpha · 06/16 15:44
Alector to Participate in the Goldman Sachs 43rd Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., June 08, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced management will participate in a fireside chat at the Goldman Sachs 43rd Annual...
GlobeNewswire · 06/08 11:00
Morgan Stanley updates biotechs with negative enterprise values & 2022 catalysts
Reviewing its coverage on biotechs with negative enterprise values, Morgan Stanley says that the number of companies on the list with potential catalysts in 2022 has increased to 27 in
Seekingalpha · 05/31 01:06
Shareholders in Alector (NASDAQ:ALEC) are in the red if they invested a year ago
It's easy to match the overall market return by buying an index fund. When you buy individual stocks, you can make...
Simply Wall St. · 05/28 12:20
Alector Reports Inducement Grants as permitted by the Nasdaq Listing Rules
SOUTH SAN FRANCISCO, Calif., May 27, 2022 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering immuno-neurology, today announced that the compensation committee of Alector’s board of directors granted Gary Rom...
GlobeNewswire · 05/27 20:30
--Barclays Adjusts Alector's Price Target to $14 from $42, Keeps Overweight Rating
MT Newswires · 05/11 12:48
More
No Data
Learn about the latest financial forecast of ALEC. Analyze the recent business situations of Alector through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

40.00%Strong Buy
40.00%Buy
10.00%Hold
10.00%Under-perform
0.00%Sell
Analyst Price Target
The average ALEC stock price target is 27.63 with a high estimate of 54.00 and a low estimate of 6.00.
High54.00
Average27.63
Low6.00
Current 11.75
EPS
Actual
Estimate
-0.030.631.291.95
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 209
Institutional Holdings: 60.80M
% Owned: 73.85%
Shares Outstanding: 82.33M
TypeInstitutionsShares
Increased
59
5.11M
New
18
1.39M
Decreased
51
3.98M
Sold Out
21
2.29M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.92%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Co-Founder/Director
Tillman Gerngross
President
Saraswati Kenkare-mitra
Chief Executive Officer/Co-Founder/Director
Arnon Rosenthal
Chief Financial Officer
Marc Grasso
Other
Siang-Shu King
Other
Gary Romano
Lead Director/Independent Director
Louis Lavigne
Independent Director
Elizabeth Garofalo
Independent Director
Paula Hammond
Independent Director
Terry Mcguire
Independent Director
Richard Scheller
Independent Director
David Wehner
Independent Director
Kristine Yaffe
No Data
No Data
About ALEC
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL002, AL003, and AL101. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ALEC stock methods without spending real money on the virtual paper trading platform.